Celecoxib is effective for treating BPH patients with refractory nocturia, researchers in Iran reported in Urology (2008; online ahead of print).
The finding, by Siavash Falahatkar, MD, and colleagues at the Guilan University of Medical Sciences in Rasht, is based on a study of 80 such patients randomly assigned to receive either celecoxib or placebo.
The mean nocturnal frequency decreased significantly from 5.17 to 2.5 in the celecoxib group; it decreased from 5.30 to 5.12 in the placebo group, a non-significant change. The mean International Prostate Symptom Score (IPPS) decreased significantly from 18.2 to 4.2 in the celecoxib group and non-significantly from 18.4 to 18 among placebo recipients.
The investigators observed no significant difference in peak flow rate between the celecoxib and placebo arms and or in the celecoxib group between baseline and one month.
To be included in the study, men needed to have an IPPS greater than 8 and complains of two or more voids nightly.